Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Melanoma 53Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 32Neoplasms 29Neoplasm Metastasis 24Colorectal Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 18Stomach Neoplasms 16Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Lung Neoplasms 11Hodgkin Disease 11Carcinoma, Transitional Cell 10Advanced Cancer 9Sarcoma 8Recurrence 8Head and Neck Neoplasms 8Solid Tumor 7Prostatic Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Carcinoma, Merkel Cell 6Breast Neoplasms 6Mesothelioma 5Glioblastoma 5

Interventions

Gemcitabine 3Capecitabine 3tivozanib 2pembrolizumab 2Oxaliplatin 2Cisplatin 2trametinib 1tislelizumab 1spartalizumab 1silmitasertib 1pertuzumab 1olutasidenib 1devimistat 1atezolizumab 1Sorafenib 1Ritonavir 1Pemetrexed 1Nivolumab 1Itraconazole 1Ipilimumab 1Epirubicin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bile Duct Neoplasms × Nivolumab × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡